DrugPatentWatch Database Preview
Drugs in Development Information for LY03005
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug LY03005?
LY03005 is an investigational drug.
There have been 7 clinical trials for LY03005.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 27th 2017.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Luye Pharma Group Ltd., Shandong Luye Pharmaceutical Co., Ltd., and [disabled in preview].
There are four US patents protecting this investigational drug and forty-three international patents.
Summary for LY03005
| US Patents | 4 |
| International Patents | 43 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2017-11-27) |
| Vendors | 0 |
Recent Clinical Trials for LY03005
| Title | Sponsor | Phase |
|---|---|---|
| A Relative Bioavailability Food Effect Study of LY03005 | Luye Pharma Group Ltd. | Phase 1 |
| A Cross-over Relative Bioavailability (RBA) Study of LY03005 vs Pristiq | Luye Pharma Group Ltd. | Phase 1 |
| Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® | Luye Pharma Group Ltd. | Phase 1 |
Clinical Trial Summary for LY03005
Top disease conditions for LY03005
Top clinical trial sponsors for LY03005
US Patents for LY03005
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY03005 | Start Trial | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | Shandong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Zhuzhou, Hunan, CN) | Start Trial |
| LY03005 | Start Trial | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | Shandong Luye Pharmaceutical Co. Ltd. (Yantai, CN) Li; Youxin (Zhuzhou, CN) | Start Trial |
| LY03005 | Start Trial | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same | Shangong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Langenfeld, DE) | Start Trial |
| LY03005 | Start Trial | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (Yantai, CN) Li; Youxin (Langenfield, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LY03005
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LY03005 | Australia | 2006257558 | 2025-06-17 | Start Trial |
| LY03005 | Canada | 2612413 | 2025-06-17 | Start Trial |
| LY03005 | China | 1955159 | 2025-06-17 | Start Trial |
| LY03005 | Denmark | 1897867 | 2025-06-17 | Start Trial |
| LY03005 | European Patent Office | 1897867 | 2025-06-17 | Start Trial |
| LY03005 | Spain | 2624789 | 2025-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
